Workshop report: Schistosomiasis vaccine clinical development and product characteristics. (Q39256776)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26721329 AND SRC:MED&resulttype=core&format=json

3 March 2020

title

Workshop report: Schistosomiasis vaccine clinical development and product characteristics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26721329 AND SRC:MED&resulttype=core&format=json

3 March 2020

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26721329 AND SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Annie X Mo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26721329 AND SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

22 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26721329 AND SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26721329 AND SRC:MED&resulttype=core&format=json

3 March 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26721329 AND SRC:MED&resulttype=core&format=json

3 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26721329 AND SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

995-1001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26721329 AND SRC:MED&resulttype=core&format=json

Schistosomiasis elimination strategies and potential role of a vaccine in achieving global health goals

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

A new approach to modelling schistosomiasis transmission based on stratified worm burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

The economic value of a visceral leishmaniasis vaccine in Bihar state, India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Modeling the economic value of a Chagas' disease therapeutic vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Preclinical Prophylactic Efficacy Testing of Sm-p80–Based Vaccine in a Nonhuman Primate Model of Schistosoma mansoni Infection and Immunoglobulin G and E Responses to Sm-p80 in Human Serum Samples From an Area Where Schistosomiasis Is Endemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Differential anti-glycan antibody responses in Schistosoma mansoni-infected children and adults studied by shotgun glycan microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Enhancement of protective efficacy through adenoviral vectored vaccine priming and protein boosting strategy encoding triosephosphate isomerase (SjTPI) against Schistosoma japonicum in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Schistosoma japonicum triose-phosphate isomerase plasmid DNA vaccine protects pigs against challenge infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Development of Paramyosin as a Vaccine Candidate for Schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Suppression of the Insulin Receptors in Adult Schistosoma japonicum Impacts on Parasite Growth and Development: Further Evidence of Vaccine Potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

The Human Hookworm Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Sensitivity and Specificity of a Urine Circulating Anodic Antigen Test for the Diagnosis of Schistosoma haematobium in Low Endemic Settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Human IgE responses to different splice variants of Schistosoma mansoni tropomyosin: associations with immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Immuno-evasive tactics by schistosomes identify an effective allergy preventative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

Human schistosomiasis: potential consequences of vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032

A multi-component integrated approach for the elimination of schistosomiasis in the People's Republic of China: design and baseline results of a 4-year cluster-randomised intervention trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2015.12.032